UNCY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:00):

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury...

Stats
Today's Volume	273 187
Average Volume	414 979
Market Cap	39.27M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-0.180 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.880
ATR14	$0.00500 (0.44%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Townsend John	Buy	228 119	Stock Options
2024-04-15	Jermasek Douglas	Buy	463 250	Stock Options
2024-04-15	Gupta Pramod	Buy	463 250	Stock Options
2024-04-15	Gupta Shalabh K.	Buy	1 319 583	Stock Options
2023-09-05	Laumas Sandeep	Buy	189 236	Stock Options

INSIDER POWER
99.85
Last 57 transactions
Buy: 72 376 966 \| Sell: 337 849

Volume Correlation

Long: 0.40 (neutral)

Short: 0.99 (very strong)

Signal:(66.584) Expect same movement, but be aware

Unicycive Therapeutics, Correlation

10 Most Positive Correlations
PXLW	0.932
LXRX	0.927
CYBR	0.926
NWSA	0.92
IMNM	0.919
ALLO	0.917
FWRG	0.916
FATE	0.915
CREX	0.913
TNYA	0.912

10 Most Negative Correlations
CMLT	-0.954
ITAC	-0.937
CFACU	-0.931
RTPY	-0.928
CENH	-0.927
GCAC	-0.921
GIAC	-0.92
MCAE	-0.919
CMLTU	-0.915
CTAC	-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Unicycive Therapeutics, Correlation - Currency/Commodity

-0.53
( weak negative )

-0.35
( neutral )

0.00
( neutral )

0.61
( weak )

0.30
( neutral )

Unicycive Therapeutics, Financials

Annual	2023
Revenue:	$675 000
Gross Profit:	$391 000 (57.93 %)
EPS:	$-1.240

FY	2023
Revenue:	$675 000
Gross Profit:	$391 000 (57.93 %)
EPS:	$-1.240

FY	2022
Revenue:	$951 000
Gross Profit:	$944 000 (99.26 %)
EPS:	$-1.200

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.691

Financial Reports:

No articles found.

Unicycive Therapeutics,